Blocking Fat Absorption With Orlistat Increases Appetite and Reduces GLP-1: Gut Fat Signal Explained
Orlistat (fat absorption blocker) acutely increased appetite and reduced postprandial GLP-1 responses, proving that fat must be absorbed (not just present) to trigger satiety hormones — the gut needs to process fat to signal fullness.
Quick Facts
What This Study Found
Orlistat inhibition of intestinal lipase acutely increased appetite and attenuated GLP-1/PYY satiety responses, proving that fat absorption (not just fat presence) is required for satiety hormone release — the gut must PROCESS fat to signal fullness.
Key Numbers
How They Did This
RCT study.
Why This Research Matters
Relevant for glp-1, neuropeptides, weight-loss.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Orlistat inhibition of intestinal lipase acutely increased appetite and attenuated GLP-1/PYY satiety responses, proving that fat absorption (not just
- Evidence Grade:
- strong evidence.
- Study Age:
- Published in 2008.
- Original Title:
- Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
- Published In:
- The Journal of clinical endocrinology and metabolism, 93(10), 3995-8 (2008)
- Authors:
- Ellrichmann, Mark, Kapelle, Mario, Ritter, Peter R, Holst, Jens J, Herzig, Karl-Heinz, Schmidt, Wolfgang E, Schmitz, Frank, Meier, Juris J
- Database ID:
- RPEP-01336
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Blocking Fat Absorption With Orlistat Increases Appetite and Reduces GLP-1: Gut Fat Signal Explained
What was found?
Orlistat (fat absorption blocker) acutely increased appetite and reduced postprandial GLP-1 responses, proving that fat must be absorbed (not just present) to trigger satiety hormones — the gut needs to process fat to signal fullness.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01336APA
Ellrichmann, Mark; Kapelle, Mario; Ritter, Peter R; Holst, Jens J; Herzig, Karl-Heinz; Schmidt, Wolfgang E; Schmitz, Frank; Meier, Juris J. (2008). Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.. The Journal of clinical endocrinology and metabolism, 93(10), 3995-8. https://doi.org/10.1210/jc.2008-0924
MLA
Ellrichmann, Mark, et al. "Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.." The Journal of clinical endocrinology and metabolism, 2008. https://doi.org/10.1210/jc.2008-0924
RethinkPeptides
RethinkPeptides Research Database. "Orlistat inhibition of intestinal lipase acutely increases a..." RPEP-01336. Retrieved from https://rethinkpeptides.com/research/ellrichmann-2008-orlistat-inhibition-of-intestinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.